ARCH Venture Partners: Partnering with University Researchers to Build Life Sciences Platforms

What we found

The funds

ARCH Venture Partners manages a portfolio of funds with varying capitalization levels. The firm’s ARCH Venture Fund XII is reported at $3 billion, while a separate figure for the same fund stands at $2.975 billion as of 2021. ARCH Venture Fund XI is listed at $1.941 Billion as of 2021. More recently, ARCH Venture Partners Fund XIII is described as $3B+ as of 2024. Additionally, a specific entry for ARCH Venture Partners indicates a value of $50K as of 2024. [4] [5]

Portfolio outcomes

As of 2022, ARCH Venture Partners has achieved more than 100 portfolio exits, according to data from sparkco.ai. Other records from the same source and time period indicate that the firm has realized over 300 portfolio exits. In addition to these aggregate exit figures, specific transaction details are available for DA32 Life Science Tech Acquisition Corp. This entity conducted an initial public offering valued at $200 Million, as reported by ipo-edge.com. The IPO involved the issuance of 20,000,000 shares. The price per share for this offering was set at $10.00. These financial metrics provide a snapshot of the scale of specific transactions associated with the broader venture ecosystem in which ARCH Venture Partners operates. The data points regarding the number of exits vary between the two cited figures of 100+ and 300+, both attributed to sparkco.ai for the year 2022. The IPO details for DA32 Life Science Tech Acquisition Corp. are consistently sourced from ipo-edge.com, confirming the total value, share count, and pricing structure of that specific event. [6] [14]

The firm

ARCH Venture Partners was established in 1986. The firm operates as a venture capital company with offices located in Austin, Chicago, New York, and Seattle. Its investment strategy focuses on three primary sectors: life sciences, information technology, and physical sciences. The firm invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers. In this capacity, ARCH Venture Partners acts as a company-builder partner to commercialize frontier biology. The organization is also known as Arch Development Corporation, a name associated with its founding in 1986. The firm’s approach involves direct collaboration with academic institutions to develop new scientific platforms. It targets early-stage opportunities where it can play a foundational role in company creation. The geographic presence in four major cities supports its operational model. The focus on deep science and life sciences distinguishes its portfolio strategy. By working directly with university researchers, the firm aims to translate academic discoveries into commercial entities. This model emphasizes building companies from the ground up rather than merely providing capital. The firm’s activities are centered on the commercialization of frontier biology and other deep-science areas. Its presence in Austin, Chicago, New York, and Seattle facilitates access to diverse research ecosystems. The establishment date of 1986 marks the beginning of its operations in the venture capital space. The firm continues to operate under the name ARCH Venture Partners, maintaining its focus on life sciences, information technology, and physical sciences. [1] [2] [6] [7]

The people

Inca Coman, Ph.D., serves as a Venture Partner with ARCH, where she works to source and evaluate investment opportunities across the biotech and healthcare sectors. She is also a co-founder and Vice President of Business Development at Vilya. Additionally, Coman is a co-founder of RIPPL Care and was part of the founding team at Paradigm. She has held the position of Venture Entrepreneurial Fellow at Flagship Pioneering. Coman acts as a biotech and healthcare consultant for startups in Madison, WI. Her academic background includes a B.A. in Biology from Occidental College and a Ph.D. in Neuroscience from the University of Wisconsin-Madison. She has authored multiple peer-reviewed articles in Nature journals. Her research experience includes work with the Planetary Protection Group at NASA’s Jet Propulsion Laboratory. She also launched an international research project with the Organization for Tropical Studies in Costa Rica, Occidental College, and UCLA. ARCH Venture Partners has a managing partner and co-founder associated with the firm, with figures of 15,000, 15%, and 20% noted in connection with this role. [3] [8]

What the firm says

ARCH Venture Partners states that after more than 38 years, its investment philosophy has remained consistent: betting on great science and great teams to build breakthrough companies. The firm believes that AI and new data-driven insights into biology will help enable a more preventive, curative, and equitable healthcare system. ARCH describes itself as first and foremost a company builder, fostering innovation at scale to develop new technologies and medicines as rapidly as possible. It notes a long history of identifying top forward-looking trends in life sciences R&D and the individuals driving truly breakthrough scientific hypotheses. The firm creates and invests in groundbreaking life science and technology companies. Its ARCH Venture Fund XIII is valued at $3 billion as of September 26, 2024. The ARCH Venture Fund XII is valued at $2.975 billion as of June 2022. Fund XI is listed at $1.941 Billion as of 2021, while other sources cite $1.85 Billion. The firm reported $7.4B+ AUM in 2023 firm disclosures. [6] [9] [10] [11] [12] [13]

What the press says

ARCH Venture Partners is reported to have $25 million in assets as of 2026, according to data from www.cbinsights.com. The firm’s Arch Venture Fund V is listed at $300 million as of 1993, per information from www.wisconsin.edu. Dr. Inca Coman serves as a Venture Partner with ARCH, where she works to source and evaluate investment opportunities across biotech and healthcare. She is also Co-founder and Vice President of Business Development at Vilya, an ARCH portfolio company. Dr. Coman has been involved in company creation and portfolio operations, including serving as Co-founder of RIPPL Care and joining the founding team of Paradigm. Before joining ARCH, she was a Venture Entrepreneurial Fellow at Flagship Pioneering, creating scientific venture opportunities. She has authored multiple peer-reviewed articles in Nature journals and worked as a biotech and healthcare consultant for startups in Madison, WI, during her Ph.D. training. [1] [2] [3]

Where the sources disagree

• The founding year of 1986 is not independently verified, as it appears only on secondary hosts rather than primary sources or data publishers. [2] [6]
• The reported funds raised figure of $2.975 billion lacks independent verification, appearing only on secondary hosts rather than primary sources or data publishers. [6] [9] [10] [11]

Analysis

The firm has raised $10.9 billion across five events between 2021 and 2024, representing the total scale of the funds you are being asked to join. This figure defines the magnitude of the capital pool associated with the manager's recent fundraising activity. [5] [6] [9] [12]

The specific figure of $2.975 billion is repeated across four hosts, including the firm's own website, but none are primary sources or independent data publishers. This means the headline number is self-reported by the firm rather than verified by an external authority. [6] [9] [10] [11]

The founding date of 1986 appears on two hosts, neither of which is a primary source or data publisher. Consequently, this historical detail is the firm's own claim repeated in secondary locations rather than an independently reported fact. [2] [6]

Pros and cons for an LP weighing a commitment to this manager

Pros

• The firm has demonstrated significant capital growth, raising Fund XII at $2.975 billion, which is substantially larger than the $1.941 billion raised for Fund XI, indicating increasing investor confidence and scale. [4] [9]
• ARCH Venture Partners has achieved a track record of over 300 portfolio exits, providing LPs with evidence of the firm's ability to successfully navigate companies through the full investment lifecycle to liquidity events. [6]
• The firm manages over $7.4 billion in assets under management, reflecting a substantial scale of operations that supports its role as a major player in the life sciences venture capital sector. [6]
• ARCH Venture Partners has successfully raised Fund XIII at $3 billion, marking a continued expansion of its fund size and reinforcing its position as a leading institution in the venture capital market. [9]

Cons

• The firm's minimum investment size is reported as low as $50,000, which may indicate a high volume of small, early-stage bets that carry higher failure rates and require significant operational oversight from the LP. [5]
• There is a significant discrepancy in reported portfolio exit counts, with figures ranging from 100+ to 300+ as of 2022, creating uncertainty about the true track record of successful liquidations and the reliability of the firm's performance metrics. [6]
• The firm's strategy involves co-founding companies directly with university researchers, which introduces execution risk and potential conflicts of interest regarding the separation of academic research and commercial venture building, potentially complicating the valuation and exit of these assets. [7]
• Key personnel, such as Inca Coman, hold multiple concurrent roles including co-founder of portfolio companies (Vilya, RIPPL Care) and venture partner at ARCH, which may lead to divided attention and potential conflicts of interest in prioritizing specific portfolio companies over others. [3]